In 2004, emtricitabine/tenofovir (brant name Truvada) was approved for use among adolescents and adults as treatment for HIV-1 in combination with other antiretroviral medications to reduce viral load and increase CD4 cell counts.
Why It Matters
Approval marked a shift toward simplifying HIV treatment into a once-daily single tablet, becoming the foundational backbone for HIV care.
